Synple’s automated synthesis technology allows discovery chemists to accelerate research and improve efficiency
Click the button below to register
and view a recording of the webinar
History has proven that automation can be an effective means of increasing productivity. However, achieving this with chemical synthesis is particularly challenging – the nature of the work makes it complex and unpredictable, and many chemists are inexperienced in handling automation. These issues put barriers in the way of appropriate workflows, wasting valuable time.
Synple’s ‘Capsule Chemistry’ synthesiser, with its pre-installed reaction protocols, provides chemists with an easy-to-use tool that makes chemical synthesis as easy as making a cup of coffee. The results are reliable and easily adapted to suit different projects, enabling scientists to do more.
The content of this free, hour-long webinar will be of interest to researchers in drug discovery research, who are looking for practical and efficient ways to increase their productivity through the use of simple and accessible automation tools.
By the end of this webinar you will…
- Have an appreciation of the challenges posed by automating chemical synthesis
- Be equipped with a firm understanding of how Synple’s ‘Capsule Chemistry’ concept works
- Understand how the digitalisation of chemistry can influence future discovery research processes
Speaker: Benedikt Wanner, CEO
Benedikt obtained his PhD in the group of professor Bode at ETH Zürich, Germany, where he began work on the ‘Capsule Chemistry’ project. Subsequently, he was awarded an ETH pioneer fellowship to develop the idea into a viable commercial product. Wanner is co-founder and CEO of Synple Chem, establishing it as a leading automated synthesis company.
Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community – and through that, we aim to accelerate access to better health for people everywhere.
We provide scientists and engineers with best-in-class lab materials, technologies and services. With the 2015 combination of EMD Millipore and Sigma-Aldrich, we now have a broad portfolio of 300,000 products and an expanded global footprint.
We are dedicated to making research and biotech production simpler, faster and safer.
The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.